MYMX News and Press, Mymetics Corp From 08/31/22

EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharma...

Mymetics (MYMX) subsidiary and Insel Gruppe AG have been awarded a grant from the Swiss Innovation Agency, which will allow Mymetics in collaboration with Bern University to start a preclinical study investigating MYMX's virosome-based COVID-19 nasal vaccine candidate to block nasal infection...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation ...

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. Under the TRANSVAC2 program, funded by the European Com...

Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. In May 2020 Mymetics and Baylor College of ...

Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine The European vaccine infrastructure, TRANSVAC2, funded by the Eu...

Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was...

Mymetics' ( OTCQB:MYMX ) subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children's Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens ...

Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine Baylor College of Medicine in Texas has deve...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...